Soluble Fcγ Receptor, FcγRIIa2, is Present in Two Forms in Human Serum and is Increased in Patients: With Stage C Chronic Lymphocytic Leukemia

References

• Anderson C.L., Looney R.J. Human leukocyte IgG Fc receptors. Immunol. Today 1986; 7: 264–266
   PubMedGoogle Scholar
• Unkeless J.C. Function and heterogeneity of human Fc receptors for immunoglobulin G. J. Clin. Znvest. 1989; 83: 355–361
   PubMed Web of Science ®Google Scholar
• Van de Winkel J. G. J., Capel P. J. A. Human IgG Fc receptor heterogeneity: molecular aspects and clinical implications. Immunol. Today 1993; 14: 215–222
   PubMedGoogle Scholar
• Qui W.Q., de Bruin D., Brownstein B., Pearse R., Ravetch J.V. Organization of the human and mouse low-affinity FcγR genes. Science 1990; 248: 732–735
   PubMed Web of Science ®Google Scholar
• Brooks D.G., Qiu W.Q., Luster A.D., Ravetch J.V. Structure and expression of human IgG FcγRII (CD32). Functional heterogeneity is encoded by the altemative spliced products of multiple genes. J. Exp. Med. 1989; 170: 1369–1386
   PubMed Web of Science ®Google Scholar
• Stuart S.G., Trounstine M.I., Vaux D. J. T., Koch T., Martens C.L., Mellman I., Moore K.W. Isolation and expression of cDNA clones encoding a human receptor for IgG (FcγRII). J. Exp. Med. 1987; 166: 1668–1684
   PubMed Web of Science ®Google Scholar
• Stengelin S., Stamenkovic I., Seed B. Isolation of cDNAs for two distinct human Fc receptors by ligand affinity cloning. EMBO J. 1988; 7: 1053–1059
   PubMed Web of Science ®Google Scholar
• Seki T. Identification of multiple isofoms of the low-affinity human IgG Fc receptor. Immunogenetics 1989; 30: 5–12
   PubMed Web of Science ®Google Scholar
• Stuart S.G., Simister N.E., Clarkson S.B., Kacinski B.M., Shapiro M., Mellman I. The low affinity Fc receptor for human IgG (hFcRII) exists as multiple isofoms in macrophages, lymphocytes and IgG transporting placental epithelium. EMBO J. 1989; 8: 3657–3666
   PubMed Web of Science ®Google Scholar
• Warmerdam P. A. M., van de Winkel J. G. J., Gosselin E.J., Capel P. J. A. Molecular basis for a polymorphism of human Fcγ receptor II (CD32). J. Exp. Med. 1990; 172: 19–25
   PubMed Web of Science ®Google Scholar
• Cassel D.L., Keller M.A., Surrey S., Schwartz E., Schreiber A.D., Rappaport E.F., McKenzie S.E. Differential expression of FcγRIIA, FcγRIIB, and FcγRIIC in hematopoietic cells: analysis of transcripts. Mol. Immunol. 1993; 30: 451–460
   PubMed Web of Science ®Google Scholar
• Rappaport E.F., Cassel D.L., McKenzie S.E., Meister R.P., Surrey S., Schreiber A.D., Schwartz E. A FcγRIIA transcnpt encoding a soluble receptor can arise by alternative splicing of the transmembrane exon (abstract). Blood 1990; 76: 191a
   Google Scholar
• De la Salle C., Esposito-Farese M.-E., Bieber T., Moncuit J., Morales M., Wollenberg A., de la Salk H., Fridman W.H., Cazenave J.-P., Teillaud J.-L., Hanau D. Release of soluble FcγRII/CD32 molecules by human Langerhans cells: a subtle balance between shedding and secretion?. J. Invest. Dennatol. 1992; 99: 15S–17S
   PubMed Web of Science ®Google Scholar
• Rappaport E.F., Cassel D.L., Walterhouse D.O., McKenzie S.E., Surrey S., Keller M.A., Schreiber A.D., Schwartz E. A soluble form of the human Fc receptor FcγRIIA: cloning, transcript analysis and detection. Exp. Hematol. 1993; 21: 689–696
   PubMed Web of Science ®Google Scholar
• Astier A., de la Salle H., de la Salle C., Bieber T., Esposito-Farese M.-E., Freund M., Cazenave J.-P., Fridman W.H., Teillaud J.-L., Hanau D. Human epidermal Langerhans cells secrete a soluble receptor for IgG (FcγRII/CD32) that inhibits the binding of immune-complexes to FcγR+ cells. J. Immunol. 1994; 152: 201–212
   PubMed Web of Science ®Google Scholar
• Gachet C., Astier A., de la Salk H., de la Salk C., Fridman W.H., Cazenave J.-P., Hanau D., Teillaud J.-L. Release of FcγRIIa2 by activated platelets and inhibition of anti-CD9-mediated platelet aggregation by recombinant FcγRIIa2. Blood 1995; 85: 698–704
   PubMed Web of Science ®Google Scholar
• Khayat D., Dux Z., Anavi R., Shlomo Y., Witz I.P., Ran M. Circulating cell free Fcγ2b/γ1 receptor in normal mouse serum: its detection and specificity. J. Immunol. 1984; 132: 2496–2501
   PubMed Web of Science ®Google Scholar
• Pure E., Dune C.J., Summerill C.K., Unkeless J.C. Identification of soluble Fc receptors in mouse serum and the conditioned medium of stimulated B cells. J. Exp. Med. 1984; 160: 1836–1849
   PubMed Web of Science ®Google Scholar
• Fridman W.H., Mathiot C., Moncuit J., Teillaud J.-L. Fc receptors, immunoglobulin-binding factors and B chronic lymphocytic leukemia. Nouv. Rev. Fr. Hématol. 1988; 30: 311–315
   PubMedGoogle Scholar
• Khayat D., Geffrier C., Yoon S., Scigliano E., Soubrane C., Weil M., Unkeless J.C., Jacquillat C. Soluble circulating Fcγ receptors in human serum. A new ELISA assay for specific and quantitative detection. J. Immunol. Methods 1987; 100: 235–241
   PubMed Web of Science ®Google Scholar
• Huizinga T. W. J., de Haas M., Kleijer M., Nuijens J.H., Roos D., von dem Borne A. E. G. K. Soluble Fcγ receptor III in human plasma originates from release by neutrophils. J. Clin. Invest. 1990; 86: 416–423
   PubMed Web of Science ®Google Scholar
• Lanier L.L., Phillips J.H., Testi R. Membrane anchoring and spontaneous release of CD16 (FcRIII) by natural killer cells and granulocytes. Eur. J. Immunol. 1989; 19: 775–778
   PubMed Web of Science ®Google Scholar
• De Haas M., Kleijer M., Minchinton R.M., Roos D., von dem Borne A. E. G. K. Soluble FcγRIIIa is present in plasma and is derived from natural killer cells. J. Immunol. 1994; 152: 900–907
   PubMed Web of Science ®Google Scholar
• Sautès C., Varin N., Teillaud C., Daëron M., Even J., Hogarth P.M., Fridman W.H. Soluble Fcγ receptors II (FcγRII) are generated by cleavage of membrane FcγRII. Eur. J. Immunol. 1991; 21: 231–234
   PubMed Web of Science ®Google Scholar
• Tartour E., de la Salk H., de la Salk C., Teillaud C., Camoin L., Galinha A., Latour S., Hanau D., Fridman W.H., Sautès C. Identification in mouse macrophages and in serum of a soluble receptor for the Fc portion of IgG (FcγR) encoded by an alternatively spliced transcript of the FcγRII gene. Int. Immunol. 1993; 5: 859–868
   PubMed Web of Science ®Google Scholar
• Astier A., de la Salk H., Freund M., Cazenave J.-P., Fridman W.H., Hanau D., Teillaud J.-L. Detection and quantification of secreted soluble FcγRIIA in human sera by an Enzyme-Linked Immunosorbent Assay. J. Immunol. Methods 1993; 166: 1–10
   PubMed Web of Science ®Google Scholar
• Khayat D., Soubrane C., Andrieu J.-M., Visonneau S., Eme D., Tourani J.-M., Beldjord K., Weil M., Fernandez E., Jacquillat C. Changes of soluble CD16 levels in serum of HIV-infected patients: correlation with clinical and biological prognostic factors. J. Infect. Dis. 1990; 161: 430–435
   PubMed Web of Science ®Google Scholar
• Mathiot C., Teillaud J.-L., Elmalek M., Mosseri L., Euller-Ziegler L., Daragon A., Groshois B., Michaux J.-L., Facon T., Bernard J.-F., Duclos B., Monconduit M., Fridman W.H. Correlation between soluble serum CD16 (sCD16) levels and disease stage in patients with multiple myeloma. J. Clin. Immunol. 1993; 13: 41–48
   PubMed Web of Science ®Google Scholar
• Sarfati M., Bron D., Lagneaux L., Fonteyn C., Frost H., Delespesse G. Elevation of IgE-Binding factors in serum of patients with B cell-derived chronic lymphocytic leukemia. Blood 1988; 71: 94–98
   PubMed Web of Science ®Google Scholar
• Binet J.-L., Auquier A., Dighiero G., Chastang C., Piguet H., Goasguen J., Vaugier G., Potron G., Colona P., Thomas M., Tchernia G., Jacquillat C., Boivin P., Lesty C., Duault M.T., Monconduit M. A new prognostic classification of chronic lymphocytic leukemia derived from a multi-variate survival analysis. Cancer 1981; 48: 198–206
   PubMed Web of Science ®Google Scholar
• Delespesse G., Sarfati M., Wu C.Y., Fournier S., Letellier M. The low affinity receptor for IgE. Immunol. Rev. 1992; 125: 77–97
   PubMed Web of Science ®Google Scholar
• De la Salk H., Teillaud J.-L., Astier A., Esposito-Farese M.-E., Faller M., Cazenave J.-P., Sautés C., Fridman W.H., Hanau D. FcγR on human dendritic cells. Human IgG Fc Receptors, J. G. J. van de Winkel, P. J. A. Capel. Landes Company, Chapman and Hall, New York 1996; 39–55
   Google Scholar
• Dighiero G., Travade P., Chevret S., Fenaux P., Chatang C., Binet J.-L., French Cooperative group on CLL. B-cell chronic lymphocytic leukemia: present status and future directions. Blood 1991; 78: 1901–1914
   PubMed Web of Science ®Google Scholar
• Van den Herik-Oudijk I.E., Westerdaal N. A. C., Henriquez N.V., Capel P. J. A., van de Winkel J. G. J. Functional analysis of human FcγRII (CD32) iso-forms expressed in B lymphocytes. J. Immunol. 1994; 152: 574–585
   PubMed Web of Science ®Google Scholar
• Sarfati M., Chevret S., Chastang C., Biron G., Stryckmans P., Delespesse G., Binet J.-L., Merle-Béral H., Bron D. Prognostic importance of serum soluble CD23 level in chronic lymphocytic leukemia. Blood 1996; 88: 4259–4264
   PubMed Web of Science ®Google Scholar
• Teillaud J.-L., Bouchard C., Astier A., Teillaud C., Tartour E., Michon J., Galinha A., Moncuit J., Mazières N., Spagnoli R., Fridman W.H., Sautès C. Natural and recombinant soluble low affinity FcγR: detection, purification and functional activities. Immunomethods 1994; 4: 48–64
   PubMedGoogle Scholar
• Teillaud C., Galon J., Zilber M.-T., Mazières N., Spagnoli R., Kurrle R., Fridman W.H., Sautès C. Soluble CD16 from neutrophils binds peripheral blood mononuclear cells and inhibits pokeweed mitogen (PWM)-induced responses. Blood 1993; 82: 3081–3090
   PubMed Web of Science ®Google Scholar
• Galon J., Bouchard C., Fridman W.H., Sautès C. Ligands and biological activities of soluble Fcγ receptors. Zrnmunol. Letters 1995; 44: 175–181
   PubMed Web of Science ®Google Scholar